S4194 • 2026

Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.*

Passed Legislature

This bill passed both chambers and reached final enrollment, even if later executive action is not shown here.

Sponsor: Vitale, Joseph F.
Last action: 2026-06-30
Official status: Substituted by A4852 (ACS)
Effective date: Not listed

Plain English Breakdown

Using official source text because the generated explanation was unavailable or could not be confirmed against the official bill text.

Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.*

Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.* Topic: Substituted by another Bill Fiscal note: This bill has not been certified by OLS for a fiscal note.

What This Bill Does

Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.* Topic: Substituted by another Bill Fiscal note: This bill has not been certified by OLS for a fiscal note.

Limits and Unknowns

This entry is temporarily using official source text because the generated explanation could not be confirmed against the official bill text during the last sync.

Bill History

2026-06-30 New Jersey Legislature
Substituted by A4852 (ACS)
2026-06-11 New Jersey Legislature
Reported from Senate Committee as a Substitute, 2nd Reading
2026-05-11 New Jersey Legislature
Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee

Official Summary Text

Revises certain requirements for prescription of Schedule II controlled dangerous substances via telemedicine and telehealth without in-person examination or review.*
Topic:
Substituted by another Bill
Fiscal note:
This bill has not been certified by OLS for a fiscal note.

Current Bill Text

Read the full stored bill text

S4194 S4210 SCS SHH Statement 6/11/26

SENATE HEALTH, HUMAN SERVICES AND SENIOR CITIZENS COMMITTEE

STATEMENT TO

SENATE COMMITTEE SUBSTITUTE
FOR

SENATE, Nos.
4194 and 4210

STATE
OF NEW JERSEY

DATED:
�JUNE
11, 2026

����� The Senate Health, Human Services and Senior Citizens
Committee reports favorably a Senate Committee Substitute for Senate Bill Nos.
4194 and 4210.

����� The substitute bill revises certain requirements for
the prescription of Schedule II controlled dangerous substances via
telemedicine and telehealth without in-person examination or review.

����� The substitute bill amends N.J.S.A.45:1-62 to
eliminate the in-person examination or review requirement for the prescription
of Schedule II controlled dangerous substances through the use of telemedicine
or telehealth: to patients, who are currently in active treatment for cancer,
receiving hospice care from a licensed hospice or palliative care, or are
residents of a long-term care facility; to patients, who are undergoing
evaluation, consultation, or treatment related to P.L.2019, c.59 (C.26:16-1 et
seq.); or for any medications that are being prescribed to a patient for use in
the treatment of substance use disorder.

����� The substitute bill provides specific requirements for
the prescription of a stimulant which is a Schedule II controlled dangerous
substance through the use of telemedicine or telehealth to an adult patient.

����� The substitute bill provides that the prescription of
Schedule II controlled dangerous substances to a patient through the use of
telemedicine or telehealth will only be authorized when the prescribing health
care provider is using interactive, real-time, two-way audio and visual
technologies when treating the patient and the use of such technologies is consistent
with State and federal law, including without limitation that the provider
meets the same standard of care or practice standards as are applicable to
in-person settings.